BDTX

Black Diamond Therapeutics Stock Analysis

AI Rating

Good
  • Quality1/10
  • Growth 7/10
  • Value 4/10
Black Diamond Therapeutics sales and earnings growth
BDTX Growth
Good
  • Revenue Y/Y -100.00%
  • EPS Y/Y -1062.50%
  • FCF Y/Y -374.02%
Black Diamond Therapeutics gross and profit margin trends
BDTX Profitability
Low
  • Gross margin 0.00%
  • EPS margin 0.00%
  • ROIC 5Y -39.56%
Black Diamond Therapeutics net debt vs free cash flow
BDTX Risk
Great
  • Debt / Equity 0.1
  • Debt / FCF 0.0
  • Interest coverage NA

Black Diamond Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks